Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence

Author:

Jovanoski Nick1,Bowes Kathleen2,Brown Audrey2,Belleli Rossella1,Di Maio Danilo1,Chadda Shkun2,Abogunrin Seye1ORCID

Affiliation:

1. F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Building 002/OG18, CH-4070, Basel, Switzerland

2. Genesis Research, West One, Forth Banks, Newcastle, NE1 3PA, UK

Abstract

Aim: Assess the long-term survival and quality-of-life outcomes in early-stage NSCLC (eNSCLC) patients. Methods: Review of long-term survival and quality-of-life after curative treatment in eNSCLC patients in observational studies. Results: Disease-free proportion decreased in stage III vs stage I patients. Recurrence-free proportion decreased with age and disease stage. Advanced stage and vascular invasion increased risk of late recurrence. Conditional 5-year relative survival rates did not exceed 87%, indicating higher mortality in eNSCLC survivors. Lower conditional survival rates and relative survival rates were associated with older age and advanced disease. Survivors of eNSCLC had poorer physical quality-of-life. Conclusion: Despite curative-intent therapy, survivors of eNSCLC still face significant risks of recurrence, excess mortality, and diminished quality-of-life.

Funder

F. Hoffmann-La Roche

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference57 articles.

1. American Cancer Society. Key Statistics for Lung Cancer (2022). www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html

2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

3. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

4. World Health Organization. International Agency for Research on Cancer Globocan Europe Fact Sheet 2020 (2020). https://gco.iarc.fr/today/data/factsheets/populations/908-europe-fact-sheets.pdf

5. American Society of Clinical Oncology. Lung cancer – non-small cell: introduction (2021). www.cancer.net/cancer-types/lung-cancer-non-small-cell/introduction

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3